Skip to main content

Table 1 Patient characteristics of all studied patients

From: Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study

 

N (%)

Patient Number

969 (100.0)

Gender

  Male

591 (61.0)

  Female

378 (39.0)

Age at treatment (years)

  Mean (SD)

60.01 (12.11)

  Median (min, max)

60 (22, 96)

Side

  Left (splenic flexture to rectum)

765 (78.9)

  Right (cecum to hepatic flexture)

136 (14.0)

  Transverse

58 (6.0)

  Unknown

10 (1.0)

Histology

  Adenocarcinoma

938 (96.8)

  Others

31 (3.2)

Grade

  1

46 (4.7)

  2

738 (76.2)

  3

103 (10.6)

Undifferentiated

6 (0.6)

Unknown

76 (7.8)

Stage at diagnosisa

  I-III

419 (43.2)

  IV

550 (56.8)

Time interval from diagnosis date to first prescription of Cetuximab

  Mean months (SD)

26.4 (15.3)

Cetuximab combination with chemotherapy

961 (99.2)

Chemotherapy after end of Cetuximab

532 (54.9 %)

Death

806 (83.2)

Follow-up (months)

  Mean (SD)

12.8 (8.6)

  Median (min, max)

11.3 (0.1, 39.4)

  1. Abbreviation: SD standard deviation
  2. aby American Joint Cancer Committee on Cancer (AJCC) system, 6th edition